NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Should l Buy ?
Source: PRnewswire
Merger Announcement: NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced an update regarding their proposed merger, aimed at enhancing their capabilities in treating CNS disorders and neurodegenerative diseases.
Company Profiles: NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company, while Kadimastem is an advanced clinical-stage cell therapy company focused on neurodegenerative diseases and diabetes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
